Quantitation of the molecular mechanisms of biological synergism in a mixture of DNA-acting aromatic drugs

Biophysical Chemistry

Volumn 132, Issue 2-3, 2008, Pages 148-158

  Evstigneev, M P ^a   Lantushenko, A O ^a   Evstigneev, V P ^a   Mykhina, Yu V ^a   Davies, D B ^b  

^a SEVASTOPOL STATE UNIVERSITY   (Russian Federation)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aromatic drugs; Competitive binding; Hetero association; Interceptor; Protector

Indexed keywords

DNA;

ANALYTIC METHOD; ARTICLE; COMPLEX FORMATION; DNA BINDING; EQUILIBRIUM CONSTANT; PRIORITY JOURNAL;

BINDING SITES; DNA; DRUG SYNERGISM; METHODS; MODELS, CHEMICAL; MODELS, THEORETICAL; RECEPTORS, DRUG;

EID: 37049013688     PISSN: 03014622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpc.2007.11.001     Document Type: Article

References (80)

1. Chu E., and DeVita V.T. Physicians' cancer chemotherapy drug manual (2003), Jones and Bartlett Publ., London
2. Stockley I.H. Stockley's Drug Interactions. 6th ed., (2002), Pharm. Press, London
3. Neidle S., and Waring M.J. Molecular aspects of Anti-cancer drug action (1983), Macmillan, London
4. Pullman B. Molecular mechanism of specifity in DNA-antitumor drug interactions. Adv. Drug Res. 18 (1989) 2-112
5. Graves D.E., and Velea L.M. Intercalative binding of small molecules to nucleic acids. Curr. Org. Chem. 4 (2000) 915-928
6. Brana M.F., Cacho M., Gradillas A., de Pascual-Teresa B., and Ramos A. Intercalators as anticancer drugs. Curr. Pharm. Des. 7 (2001) 1745-1780
7. Yao S., Murali D., Seetharamulu P., Haridas K., Petluru P.N.V., Reddy D.G., and Hausheer F.H. Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of Topoisomerase I. Cancer Res. 58 (2001) 3782-3786
8. Arcamone F., Animati F., Capranico G., Lombarda P., Pratesi G., Manzini S., Supino R., and Zunino F. New developments in antitumor anthracyclines. Pharmacol. Ther. 76 (1997) 117-124
9. Chaires J.B. Drug-DNA interactions. Curr. Opin. Struct. Biol. 8 (1998) 314-320
10. Monneret C. Recent developments in the field of antitumour anthracyclines. Eur. J. Med. Chem. 36 (2001) 483-493
11. Baker L.H., Frank J., Fine G., Balcerzak S.P., Stephens R.L., Stuckey W.J., Rivkin S., Saiki J., and Ward J.H. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin-D for advanced soft-tissue sarcomas: a randomized comparative trial. A phase-III, Southwest-Oncology-Group-Study. J. Clin. Oncol. 5 (1987) 851-861
12. Dunst J., Ahrens S., Paulussen M., Rube C., Winkelmann W., Zoubek A., Harms D., and Jurgens H. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studie. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 379-384
13. Bontenbal M., Planting A.S.T., Rodenburg C.J., Dees A., Verweij J., Bartels C.C.M., Alexievafigusch J., Vanputten W.L.J., and Klijn G.J.M. Weekly low-dose mitoxantrone plus doxorubicin as 2nd-line chemotherapy for advanced breast-cancer. Breast Cancer Res. Treat. 21 (1992) 133-138
14. Kano Y., Suzuki K., Akutsu M., and Suda K. Effects of mitoxantrone in combination with other anticancer agents on a human leukemia-cell line. Leukemia 6 (1992) 440-445
15. Schaich M., Illmer T., Aulitzky W., Bodenstein H., Clemens M., Neubauer A., Repp R., Schakel U., Soucek S., Wandt H., and Ehninger G. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for patients aged 61-65 years with acute myeloid leukemia. Haematologica 87 (2002) 808-815
16. Hochsmann B., Griesshammer M., and Bergmann L. A new combination therapy with topotecan, cytarabine and mitoxantrone in patients with refractory or relapsed acute myeloid leukemia or blast crisis of chronic myeloid leukemia. Blood 94 (1999) 230B-230B (Suppl. 1)
17. Taylor C.G., Elgie A.W., Williamson C.J., and Sargent J.M. The combination of topotecan and daunorubicin shows striking synergism in vitro in Aml. Leukemia. 15 (2001) 492-492
18. Iliakis G., Nusse M., Ganapathi R., Egner J., and Yen A. Differential reduction by caffeine of adriamycin induced cell killing and cell cycle delays in Chinese hamster V79 cells. Int. J. Radiat. Oncol. Biol. Phys. 12 (1986) 1987-1995
19. Traganos F., Kaminska-Eddy B., and Darzynkiewicz Z. Caffeine reverses the cytotoxic and cell kinetic effects of Novatrone (mitoxantrone). Cell Prolif. 24 (1991) 305-319
20. Traganos F., Kapuscinsky J., and Darzynkiewicz Z. Caffeine Modulates the Effects of DNA-intercalating Drugs in Vitro: A Flow Cytometric and Spectrophotometric Analysis of Caffeine Interaction with Novatrone, Doxorubicin, Ellipticine, and the Doxorubicin Analogue AD198. Cancer Res. 51 (1991) 3682-3689
21. Traganos F., Kapuscinski J., Gong J.P., Ardelt B., Darzynkiewicz R.J., and Darzynkiewicz Z. Caffeine prevents apoptosis and cell-cycle effects induced by camptothecin or topotecan in HL-60 cells. Cancer Res. 53 (1993) 4613-4618
22. Perez C., Pelayo F., Vilaboa N.E., and Aller P. Caffeine attenuates the action of amsacrine and etoposide in U-937 cells by mechanisms which involve inhibition of RNA-synthesis. Int. J. Cancer 57 (1994) 889-893
23. Piosik J., Zdunek M., and Kapuscinski J. The modulation by xanthines of the DNA-damaging effect of polycyclic aromatic agents. Part II. The stacking complexes of caffeine with doxorubicin and mitoxantrone. Biochem. Pharmacol. 63 (2002) 635-646
24. Hartman P.E., and Shankel D.M. Antimutagens and Anticarcinogens - a survey of putative interceptor molecules. Environ. Mol. Mutagen. 15 (1990) 145-182
25. Gentile G.M., Rahimi S., Zwiesler J., Gentile G.J., and Ferguson L.R. Effect of selected antimutagens on the genotoxicity of antitumor agents. Mutat. Res. 402 (1998) 289-298
26. Amara-Mokrane Y.A., Lehucher M.P., Balansard G., Dumenil G., and Botta A. Protective effects of α-hedrin, chlorophyllin and ascorbic acid towards the induction of micronuclei by doxorubicin in cultured human lymphocytes. Mutagenesis 11 (1996) 161-167
27. Raiczyk G.B., Rivlin R.S., and Pinto J. Enhancement of adriamycin-induced mortality during riboflavin administration and riboflavin deficiency in rats. Proc. Soc. Exp. Biol. Med. 188 (1988) 495-499
28. Shinozawa S., Gomita Y., and Araki Y. Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid-peroxidation in mice and rats. Biol. Pharm. Bull. 16 (1993) 1114-1117
29. Kimura H., and Aoyama T. Decrease in sensitivity to ethidium bromide by caffeine, dimethylsulfoxide or 3-aminobenzamide due to reduced permeability. J. Pharmacobiodyn 12 (1989) 589-595
30. Arimoto S., Fukuoka S., Itome C., Nakano H., Rai H., and Hayatsu H. Binding of polycyclic planar mutagens to chlorophyllin resulting in inhibition of the mutagenic activity. Mutat. Res. 287 (1993) 293-305
31. Wood A.W., Sayer J.M., Newmark H.L., Yagi H., Michaud D.P., Jerina D.M., and Conney A.H. Mechanism of the inhibition of mutagenicity of a benzo[a]pyrene 7,8-diol 9,10-epoxide by riboflavin 5′-phosphate. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 5122-5126
32. 1: a review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Mutat. Res. 399 (1998) 245-253
33. Webster R.P., Gawde M.D., and Bhattacharya R.K. Modylation of carcinogen-induced DNA damage and repair enzyme reactivity by dietary riboflavin. Cancer Lett. 98 (1996) 129-135
34. Ardelt B., Kunicki J., Traganos F., and Darzynkiewicz Z. Chlorophyllin protects cells from the cytostatic and cytotoxic effects of quinacrine mustard but not of nitrogen mustard. Int. J. Oncol. 18 (2001) 849-853
35. Kapuscinski J., Ardelt B., Piosik J., Zdunek M., and Darzynkiewicz Z. The modylation of the DNA-damaging effect of polycyclic aromatic agents by xanthines. Part I. Reduction of cytostatic effects of quinacrine mustard by caffeine. Biochem. Pharmacol. 63 (2002) 625-634
36. Piosik J., Ulanowska K., Gwizdek-Wisniewska A., Czyz A., Kapuscinski J., and Wegrzyn G. Alleviation of mutagenic effects of polycyclic aromatic agents (quinacrine mustard, ICR-191 and ICR-170) by caffeine and pentoxifylline. Mutat. Res. 530 (2003) 47-57
37. Zdunek M., Piosik J., and Kapuscinski J. Thermodynamical model of mixed aggregation of ligands with caffeine in aqueous solution. Part II. Biophys.Chemist. 84 (2000) 77-85
38. Larsen R.W., Jasuja R., Hetzler R., Muraoka P.T., Andrada V.G., and Jameson D.M. Spectroscopic and molecular modelling studies of caffeine complexes with DNA intercalators. Biophys. J. 70 (1996) 443-452
39. Lyles M.B., Cameron I.L., and Rawls H.R. Structural basis for the binding affinity of xanthines with the DNA intercalator acridine orange. J. Med. Chem. 44 (2001) 4650-4660
40. Lyles M.B., and Cameron I.L. Interactions of the DNA intercalator acridine orange, with itself, with caffeine, and with double stranded DNA. Biophys. Chemist. 96 (2002) 53-76
41. Lyles M.B., and Cameron I.L. Caffeine and other xanthines as cytochemical blockers and removers of heterocyclic DNA intercalators from chromatin. Cell Biol. Int. 26 (2002) 145-154
42. Davies D.B., Veselkov D.A., Evstigneev M.P., and Veselkov A.N. Self-association of the antitumour agent novatrone (mitoxantrone) and its hetero-association with caffeine. J. Chem. Soc., Perkin Trans. 2 (2001) 61-67
43. Davies D.B., Veselkov D.A., Djimant L.N., and Veselkov A.N. Hetero-association of caffeine and aromatic drugs and their competitive binding with a DNA oligomer. Eur. Biophys. J. 30 (2001) 354-366
44. Evstigneev M.P., Khomich V.V., and Davies D.B. Complexation of anthracycline drugs with DNA in the presence of caffeine. Eur. Biophys. J. 36 (2006) 1-11
45. Tachino N., Guo D., Dashwood W.M., Yamane S., Larsen R., and Dashwood R. Mechanisms of the in vitro antimutagenic action of chlorophyllin against benzo[a]pyrene: Studies of enzyme inhibition, molecular complex formation and degradation of the ultimate carcinogen. Mutat. Res. 308 (1994) 191-203
46. Pietrzak M., Wieczorek Z., Stachelska A., and Darzynkiewicz Z. Interactions of chlorophyllin with acridine orange, quinacrine mustard and doxorubicin analyzed by light absorption and fluorescence spectroscopy. Biophys. Chemist. 104 (2003) 305-313
47. Pietrzak M., Wieczorek Z., Wieczorek J., and Darzynkiewicz Z. The 'interceptor' properties of chlorophylline measured within the three-component system: intercalator-DNA-chlorophylline. Biophys. Chemist. 123 (2006) 11-19
48. Munoz M.A., Carmona C., Hidalgo J., Guardado P., and Balon M. Molecular associations of flavins with betacarbolines and related indoles. Bioorg. Med. Chem. 3 (1995) 41-47
49. Ramu A., Mehta M.M., Liu J., Turyan I., and Aleksic A. The riboflavin-mediated photooxidation of doxorubicin. Cancer Chemother. Pharmacol. 46 (2000) 449-458
50. 2) determined by NMR spectroscopy. Biophys. Chemist. 118 (2005) 118-127
51. 1H NMR study of the hetero-association of flavin-mononucleotide with mutagenic dyes: ethidium bromide and proflavine. Mol. Phys. 104 (2006) 647-654
52. Nakano N.I., and Igarashi S.J. Molecular interactions of pyrimidines, purines, and some other heteroaromatic compounds in aqueous media. Biochemistry 9 (1970) 577-583
53. 1H NMR chemical shift study. Magn. Reson. Chem. 27 (1989) 592-598
54. 1H NMR structural and thermodynamical analysis of the hetero-association of daunomycin and novatrone in aqueous solution. J. Mol. Struct. 701 (2004) 31-37
55. Davies D.B., Evstigneev M.P., Veselkov D.A., and Veselkov A.N. Hetero-association of anti-cancer antibiotics in aqueous solution: NMR and molecular mechanics analysis. Biophys. Chemist. 117 (2005) 111-118
56. 1H NMR investigation of the hetero-association of aromatic molecules in aqueous solution: factors involved in the stabilization of complexes of daunomycin and acridine drugs. Mol. Phys. 98 (2000) 1961-1971
57. Davies D.B., Veselkov D.A., and Veselkov A.N. NMR determination of the hetero-association of phenanthridines with daunomycin and their competitive binding to a DNA oligomer. Eur. Biophys. J. 31 (2002) 153-162
58. 1H NMR investigation of the hetero-association of phenanthridine dyes with daunomycin: effect of substitution of amino with azido groups in the dye chromophore. Mol. Phys. 102 (2004) 1933-1942
59. 13C-NMR studies on caffeine and its interaction with nucleic acids. Biopolymers 19 (1980) 1641-1654
60. 1H NMR studies of caffeine-5′-adenosine monophosphate and caffeine-poly(riboadenylate) interactions. Biophys. Chemist. 11 (1980) 109-119
61. Tornaletti S., Russo P., Parodi S., and Pedrini A.M. Studies on DNA binding of caffeine and derivatives: evidence of intercalation by DNA-unwinding experiments. Biochim. Biophys. Acta 1007 (1989) 112-115
62. Pangrekar J., Krishnaswamy K., and Jagadeesan V. Effects of riboflavin deficiency and riboflavin administration on carcinogen-DNA binding. Food Chem. Toxicol. 31 (1993) 745-750
63. Johnson I.M., Bhuvan Kumar S.G., and Malathi R. De-intercalation of ethidium bromide and acridine orange by xanthine derivatives and their modulatory effect on anticancer agents: a study of DNA-directed toxicity enlightened by time correlated single photon counting. J. Biomol. Struct. Dyn. 20 (2003) 677-685
64. Evstigneev M.P., Rybakova K.A., and Davies D.B. Complexation of norfloxacin with DNA in the presence of caffeine. Biophys. Chemist. 121 (2006) 84-95
65. Wang H., Zou H., and Zhang Y. Quantitative study of competitive binding of drugs to protein by microdialysis/high-performance liquid chromatography. Anal. Chem. 70 (1998) 373-377
66. Itzhaki R.F. Studies on the accessibility of deoxyribonucleic acid in deoxyribonucleoprotein to cationic molecules. Biochem. J. 122 (1971) 583-592
67. Itzhaki R.F. The arrangement of proteins on the deoxyribonucleic acid in chromatin. Biochem. J. 125 (1971) 221-224
68. Crothers D.M. Calculation of binding isotherms for heterogeneous polymers. Biopolymers 6 (1968) 575-584
69. 1H NMR investigation of self-association of aromatic drug molecules in aqueous solution. J. Chem. Soc., Faraday Trans. 92 (1996) 383-390
70. Martin R.B. Comparisons of indefinite self-association models. Chem. Rev. 96 (1996) 3043-3064
71. Veselkov A.N., Evstigneev M.P., Veselkov D.A., and Davies D.B. A generalized NMR-derived statistical-thermodynamical model of hetero-association of aromatic molecules in aqueous solution. J. Chem. Phys. 115 (2001) 2252-2266
72. Davies D.B., Eaton R.J., Baranovsky S.F., and Veselkov A.N. NMR investigation of the complexation of daunomycin with deoxytetranucleotides of different base sequence in aqueous solution. J. Biomol. Struct. Dyn. 17 (2000) 887-901
73. Collins J.M., Zaharko D.S., Dedrick R.L., and Chabner B.A. Potential roles for preclinical pharmacology in Phase I clinical trials. Cancer Treat. Rep. 70 (1986) 73-80
74. Gianni L., Vigano L., Surbone A., Ballinari D., Casali P., Tarella C., Collins J.M., and Bonadonna G. Pharmacology and clinical toxicity of 4′-iodo-4′deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in Phase I trials. J. Natl. Cancer Inst. 82 (1990) 469-477
75. Sundman-Engberg B., Tidefelt U., Gruber A., and Paul C. Intracellular concentrations of mitoxantrone in leukemia cells in vitro vs in vivo. Leuk. Res. 17 (1993) 347-352
76. Feofanov A., Sharonov S., Fleury F., Kudelina I., and Nabiev I. Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes. Biophys. J. 73 (1997) 3328-3336
77. 1H NMR spectroscopy. Russ. J. Bioorgan. Chem. 31 (2005) 453-459
78. 1H NMR analysis of the complex formation of aromatic molecules of antibiotic and vitamin in aqueous solution: Heteroassociation of actinomycin D and flavin mononucleotide. Biophysics 50 (2005) 20-27
79. M.P. Evstigneev, Intermolecular interactions of biologically active aromatic compounds and DNA in aqueous solution. DrSci thesis (Doctor of Physical and Mathematical Sciences), Kharkov National University, Ukraine, 2007.
80. 1H NMR spectroscopy data. Biophysics 47 (2002) 459-466